This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Burroughs, K. D. Articles by Walker, C. Search for Related Content PubMed PubMed Citation Articles by Burroughs, K. D. Articles by Walker, C.

Regulation of Apoptosis in Uterine Leiomyomata¹

Department of Carcinogenesis, University of Texas M. D. Anderson Cancer Center (K.D.B., K.K., S.R.H., R.F.-Y., D.T., C.W.), Smithville, Texas 78957; Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences (J.C.B.), Research Triangle Park, North Carolina 27709

Address all correspondence and requests for reprints to: Dr. Kevin D. Burroughs, Department of Carcinogenesis, University of Texas M. D. Anderson Cancer Center, Smithville, Texas 78957.

Tumors developing from hormone-dependent tissues, such as the breast and prostate, have been successfully treated in the clinic by methods of hormone ablation, and the resulting tumor regression has been shown to occur at least in part by the process of apoptosis. The growth of leiomyomas arising from uterine smooth muscle cells is similarly modulated by circulating steroid hormones and has been associated with periods of increased estrogen secretion. The inhibition of ovarian hormone production by endocrine therapy often results in the regression of these tumors, but the role of apoptosis in this process has not been elucidated. Using cell lines derived from the Eker rat model of uterine leiomyoma, we have investigated the mechanism of growth inhibition by estrogen deprivation. Estrogen-depleted medium and the antiestrogen tamoxifen significantly reduced cell numbers in culture and arrested cell proliferation, but did not induce apoptosis. However, the presence of an intact apoptotic pathway was demonstrated in these cells by serum starvation. In vivo data were in agreement with in vitro results, which showed that tamoxifen treatment does not change the apoptotic rate of leiomyoma tissues. Therefore, growth modulation of leiomyomas by hormone deprivation occurs via mechanisms independent of apoptosis, indicating a fundamental difference in the response of leiomyomas to hormone deprivation from that of tumors of the breast and prostate. These data suggest that creation of a hypoestrogenic milieu within leiomyomas reduces tumor volume without inducing a concomitant increase in the rate of apoptosis, which may be responsible for the limited effectiveness of currently available medicinal therapies.

This article has been cited by other articles:

				U. A. Kayisli, M. Berkkanoglu, G. Kizilay, L. Senturk, and A. Arici Expression of Proliferative and Preapoptotic Molecules in Human Myometrium and Leiomyoma Throughout the Menstrual Cycle Reproductive Sciences, October 1, 2007; 14(7): 678 - 686. [Abstract] [PDF]

				M.-N. Raymond, C. Bole-Feysot, Y. Banno, Z. Tanfin, and P. Robin Endothelin-1 Inhibits Apoptosis through a Sphingosine Kinase 1-Dependent Mechanism in Uterine Leiomyoma ELT3 Cells Endocrinology, December 1, 2006; 147(12): 5873 - 5882. [Abstract] [Full Text] [PDF]

				J. D. Cook, B. J. Davis, S.-L. Cai, J. C. Barrett, C. J. Conti, and C. L. Walker Interaction between genetic susceptibility and early-life environmental exposure determines tumor-suppressor-gene penetrance PNAS, June 14, 2005; 102(24): 8644 - 8649. [Abstract] [Full Text] [PDF]

				T. Maruo, N. Ohara, J. Wang, and H. Matsuo Sex steroidal regulation of uterine leiomyoma growth and apoptosis Hum. Reprod. Update, May 1, 2004; 10(3): 207 - 220. [Abstract] [Full Text] [PDF]

				S.-C. Huang, M.-J. Tang, Y.-M. Cheng, K.-F. Hsu, C.-L. Ho, and C.-Y. Chou Enhanced Polyadenosine Diphosphate-Ribosylation in Gonadotropin-Releasing Hormone Agonist-Treated Uterine Leiomyoma J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 5009 - 5016. [Abstract] [Full Text] [PDF]

				S.-C. Huang, M.-J. Tang, K.-F. Hsu, Y.-M. Cheng, and C.-Y. Chou Fas and Its Ligand, Caspases, and Bcl-2 Expression in Gonadotropin-Releasing Hormone Agonist-Treated Uterine Leiomyoma J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4580 - 4586. [Abstract] [Full Text] [PDF]

				C. L. Walker Role of Hormonal and Reproductive Factors in the Etiology and Treatment of Uterine Leiomyoma Recent Prog. Horm. Res., January 1, 2002; 57(1): 277 - 294. [Abstract] [Full Text] [PDF]

				K. D. Houston, D. S. Hunter, L. C. Hodges, and C. L. Walker Uterine Leiomyomas: Mechanisms of Tumorigenesis Toxicol Pathol, January 1, 2001; 29(1): 100 - 104. [Abstract] [PDF]

				S. D. Gamage, E. D. Bischoff, K. D. Burroughs, W. W. Lamph, M. M. Gottardis, C. L. Walker, and R. Fuchs-Young Efficacy of LGD1069 (Targretin), a Retinoid X Receptor-Selective Ligand, for Treatment of Uterine Leiomyoma J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 677 - 681. [Abstract] [Full Text]

				K. D. Burroughs, R. Fuchs-Young, B. Davis, and C. L. Walker Altered Hormonal Responsiveness of Proliferation and Apoptosis During Myometrial Maturation and the Development of Uterine Leiomyomas in the Rat Biol Reprod, November 1, 2000; 63(5): 1322 - 1330. [Abstract] [Full Text]

				C. L. Walker, K. D. Burroughs, B. Davis, K. Sowell, J. I. Everitt, and R. Fuchs-Young Preclinical Evidence for Therapeutic Efficacy of Selective Estrogen receptor Modulators for Uterine Leiomyoma Reproductive Sciences, July 1, 2000; 7(4): 249 - 256. [Abstract] [PDF]

				K. J. Hamann, J. E. Vieira, A. J. Halayko, D. Dorscheid, S. R. White, S. M. Forsythe, B. Camoretti-Mercado, K. F. Rabe, and J. Solway Fas cross-linking induces apoptosis in human airway smooth muscle cells Am J Physiol Lung Cell Mol Physiol, March 1, 2000; 278(3): L618 - L624. [Abstract] [Full Text] [PDF]

				C. Benassayag, M. J. Leroy, V. Rigourd, B. Robert, J. C. Honore, T. M. Mignot, M. C. Vacher-Lavenu, C. Chapron, and F. Ferre Estrogen receptors (ERalpha /ERbeta ) in normal and pathological growth of the human myometrium: pregnancy and leiomyoma Am J Physiol Endocrinol Metab, June 1, 1999; 276(6): E1112 - E1118. [Abstract] [Full Text] [PDF]